Limits...
Research and development in drug innovation: reflections from the 2013 bioeconomy conference in China, lessons learned and future perspectives.

Liu C, Constantinides PP, Li Y - Acta Pharm Sin B (2014)

Bottom Line: We found that a growing number of biologics in the pipeline of pharma companies with successful products already in the market though, small molecular entities have primarily dominated drug innovation.More importantly, modern and effective R&D strategies in biomedicine development to predict and evaluate efficacy and/or safety of 21st century therapeutics are urgently needed.Under the current circumstances, interdisciplinary cooperation mode and policy related to drug innovation in China were deeply discussed as well.

View Article: PubMed Central - PubMed

Affiliation: Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China.

ABSTRACT
The enormous progress biotechnology, bioinformatics and nanotechnology made in recent years provides opportunities and scientific framework for development of biomedicine and constitutes a paradigm shift in pharmaceutical R&D and drug innovation. By analyzing the data and related information at R&D level over the past decades, developmental tendency and R&D patterns were summarized. We found that a growing number of biologics in the pipeline of pharma companies with successful products already in the market though, small molecular entities have primarily dominated drug innovation. Additionally, small/medium size companies will continue to play a key role in the development of small molecule drugs and biologics in a multi-channel integrated process. More importantly, modern and effective R&D strategies in biomedicine development to predict and evaluate efficacy and/or safety of 21st century therapeutics are urgently needed. To face new challenges, developmental strategies were proposed, in terms of molecular targeted medicine, generic drugs, new drug delivery system and protein-based drugs. Under the current circumstances, interdisciplinary cooperation mode and policy related to drug innovation in China were deeply discussed as well.

No MeSH data available.


The contribution of small/medium size companies to pharmaceutical industry. (Sourced from Burrill & Co. (San Francisco). 2010 year to date (YTD) is through September 30.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4590300&req=5

f0020: The contribution of small/medium size companies to pharmaceutical industry. (Sourced from Burrill & Co. (San Francisco). 2010 year to date (YTD) is through September 30.

Mentions: Although the number of new drugs declined over the past years, the new drugs that giant pharmaceutical companies acquired from small/medium competitors were increasing (Fig. 4). In terms of the amount of new drugs at pre-clinical, phase I, II, III clinical trial stages, small/medium size companies have become major players in drug innovation, particularly with more drugs at phase II, III and on the market and which are originated from small/medium size companies. Their outputs filled the pipeline of giant companies with best-selling drugs14.


Research and development in drug innovation: reflections from the 2013 bioeconomy conference in China, lessons learned and future perspectives.

Liu C, Constantinides PP, Li Y - Acta Pharm Sin B (2014)

The contribution of small/medium size companies to pharmaceutical industry. (Sourced from Burrill & Co. (San Francisco). 2010 year to date (YTD) is through September 30.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4590300&req=5

f0020: The contribution of small/medium size companies to pharmaceutical industry. (Sourced from Burrill & Co. (San Francisco). 2010 year to date (YTD) is through September 30.
Mentions: Although the number of new drugs declined over the past years, the new drugs that giant pharmaceutical companies acquired from small/medium competitors were increasing (Fig. 4). In terms of the amount of new drugs at pre-clinical, phase I, II, III clinical trial stages, small/medium size companies have become major players in drug innovation, particularly with more drugs at phase II, III and on the market and which are originated from small/medium size companies. Their outputs filled the pipeline of giant companies with best-selling drugs14.

Bottom Line: We found that a growing number of biologics in the pipeline of pharma companies with successful products already in the market though, small molecular entities have primarily dominated drug innovation.More importantly, modern and effective R&D strategies in biomedicine development to predict and evaluate efficacy and/or safety of 21st century therapeutics are urgently needed.Under the current circumstances, interdisciplinary cooperation mode and policy related to drug innovation in China were deeply discussed as well.

View Article: PubMed Central - PubMed

Affiliation: Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China.

ABSTRACT
The enormous progress biotechnology, bioinformatics and nanotechnology made in recent years provides opportunities and scientific framework for development of biomedicine and constitutes a paradigm shift in pharmaceutical R&D and drug innovation. By analyzing the data and related information at R&D level over the past decades, developmental tendency and R&D patterns were summarized. We found that a growing number of biologics in the pipeline of pharma companies with successful products already in the market though, small molecular entities have primarily dominated drug innovation. Additionally, small/medium size companies will continue to play a key role in the development of small molecule drugs and biologics in a multi-channel integrated process. More importantly, modern and effective R&D strategies in biomedicine development to predict and evaluate efficacy and/or safety of 21st century therapeutics are urgently needed. To face new challenges, developmental strategies were proposed, in terms of molecular targeted medicine, generic drugs, new drug delivery system and protein-based drugs. Under the current circumstances, interdisciplinary cooperation mode and policy related to drug innovation in China were deeply discussed as well.

No MeSH data available.